- Home
- VSTD vs APM Comparison
VSTD vs APM Comparison
Compare VSTD & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTD
- APM
- Stock Information
- Founded
- VSTD 2016
- APM 2010
- Country
- VSTD United States
- APM United Kingdom
- Employees
- VSTD N/A
- APM N/A
- Industry
- VSTD Restaurants
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- VSTD Consumer Discretionary
- APM Health Care
- Exchange
- VSTD Nasdaq
- APM Nasdaq
- Market Cap
- VSTD 17.9M
- APM 18.9M
- IPO Year
- VSTD 2022
- APM 2018
- Fundamental
- Price
- VSTD $1.19
- APM $1.49
- Analyst Decision
- VSTD
- APM
- Analyst Count
- VSTD 0
- APM 0
- Target Price
- VSTD N/A
- APM N/A
- AVG Volume (30 Days)
- VSTD 152.5K
- APM 417.7K
- Earning Date
- VSTD 11-18-2025
- APM 04-30-2025
- Dividend Yield
- VSTD N/A
- APM N/A
- EPS Growth
- VSTD N/A
- APM N/A
- EPS
- VSTD N/A
- APM N/A
- Revenue
- VSTD $13,902,861.00
- APM N/A
- Revenue This Year
- VSTD N/A
- APM N/A
- Revenue Next Year
- VSTD N/A
- APM N/A
- P/E Ratio
- VSTD N/A
- APM N/A
- Revenue Growth
- VSTD 30.39
- APM N/A
- 52 Week Low
- VSTD $0.68
- APM $0.46
- 52 Week High
- VSTD $5.63
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- VSTD N/A
- APM 40.55
- Support Level
- VSTD N/A
- APM $1.40
- Resistance Level
- VSTD N/A
- APM $1.68
- Average True Range (ATR)
- VSTD 0.00
- APM 0.23
- MACD
- VSTD 0.00
- APM -0.05
- Stochastic Oscillator
- VSTD 0.00
- APM 7.56
About VSTD Vestand Inc. Class A Common Stock
Vestand Inc is a California-based Vestand is a fast-growing restaurant operator expanding into the real estate investment and development sector. It is a PropTech company engaged in AI-driven real estate investment and security token offerings (STOs). It provides services such as Property Acquisition, Property Development, Financial Management, and Property Management.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.